Back to All Events

Endocrinologic and Metabolic Drugs Advisory Committee

On Tuesday, June 9, 2015. the Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC)) supported, by a vote of 13-Yes to 3-No, with no abstentions, the safety and efficacy of PRALUENT (Alirocumab) for injection, submitted by Sanofi Aventis, U.S. (Sanofi) and Regeneron Pharmaceuticals, Inc. (Regeneron) for the treatment of high cholesterol in certain patient populations.